解读IRC评价标准.PPTVIP

* Then in 2010, Rosenberg published encouraging results from so-called chimeric antigen receptor therapy, or CAR therapy—a personalized treatment that involves genetically modifying a patient’s T cells to make them target tumor cells. One group, led by Carl June at the University of Pennsylvania, began reporting eye-catching responses to CAR therapy: patients with pounds of leukemia that melted away. At a meeting in New Orleans this month, June’s team and another at Memorial Sloan-Kettering Cancer Center in New York reported that the T cell therapy in their studies put 45 of 75 adults and children with leukemia into complete remission, * The apparent increases in tumor burden that sometimes precede responses in patients receiving immune therapy may reflect either continued tumor growth until a sufficient immune response develops or transient immune-cell infiltrate with or without edema. These analyses show that 9.7% (22 of 227) of treated patients, who were initially characterized as PD by WHO criteria, have evidence of activity consistent with a response to ipilimumab. * * * 解读IRC评价标准在实体瘤中的应用 Breakthrough of the year 2013 Why？ Antibodies against CTLA-4 Antibodies against PD-1 Chimeric antigen receptor therapy, or CAR therapy CAR therapy Adoptive cell transfer therapy with CAR-engineered T cells Result Immunity and Cancer: immunoediting PD-L1 in Cancer Expressed on cell surface of ~30% solid tumors and selected hematologic malignancies; Inhibits anti-tumor immune responses. PD-1 pathway immunotherapy 20~50% response rate in clinical trials PD-1 pathway antagonists show broad anti-tumor activity response in: melanoma, RCC, NSCLC, gastric, head and neck, ovarian, colon malignancies. Patterns of response to ipilimumab observed in advanced melanoma Clin Cancer Res 2009;15:7412-7420. PD? Resected metastatic melanoma tumor nodule of the lung SD may also be viewed as an indicator of meaningful therapeutic effect LATE BREAKING ABSTRACT: Pooled analysis of long-ter